๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 21 Shanghai 15 Hangzhou 8 Fuzhou 6 Chongqing 5
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing21 Shanghai15 Hangzhou8 Fuzhou6 Chongqing5
All 27 locations
Target enrolment
to

Trials with a site in Shanghai

15 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants
NCT07765160Healthy Participants, Overweight or Obese Participants
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
96
Shanghai
2026-08-30
Recruiting
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
NCT07265258Thyroid Eye Disease
Innovent Biologics (Suzhou) Co. Ltd.
Phase 4
92
Shanghai
2026-07-30
Recruiting
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
NCT07623798Relapsed or Refractory Multiple Myeloma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
255
Shanghai
2026-06-11
Recruiting
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
NCT07469800Overweight, Obesity, Hypertensive
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
336
Shanghai
2026-04-23
Active, closed
A Mutiple-dose Study of IBI3033 in Healthy Participants
NCT07456839Healthy Participants
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
8
Shanghai
2026-03-18
Active, closed
A First-in-human, Single-ascending-dose Study of IBI3033 in Healthy Participants
NCT07311226Healthy Participants
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
32
Shanghai
2025-12-31
Not yet open
Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression
NCT07199010Non-small Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Observational
50
Shanghai
2025-10
Recruiting
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
NCT07066098Pancreatic Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
201
Shanghai
2025-08-04
Recruiting
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
NCT06974812Unresectable Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
250
Fuzhou, Changsha, Shanghai
2025-04-18
Recruiting
IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
NCT06349408Locally Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
250
Beijing, Shanghai, Hangzhou
2025-01-10
Recruiting
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT06083207Multiple Myeloma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
116
Beijing, Nanning, Wuhan, Nanjing, Suzhou, Xuzhou, Nanchang, Shanghai
2024-07-29
Recruiting
A Study of IBI363 in Subjects With Advanced Malignancies
NCT06468098Advanced Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
556
Shanghai
2024-06-15
Active, closed
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer
NCT05116462Non-Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
506
Shanghai
2024-03-15
Active, closed
A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
NCT05972473Neovascular Age-related Macular Degeneration
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
600
Shanghai
2023-09-21
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

9 of the 15 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 15 studies
PhaseStudiesRecruitingShare
Phase 16340%
Phase 35333.3%
Phase 1/22213.3%
Observational106.7%
Phase 4116.7%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Innovent Biologics (Suzhou) Co. Ltd.159
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.